The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of multiple sclerosis drugs including Teva's Copaxone. The health ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis. From December 1996 through May 2024 ...

The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...

The US agency maintains that Glatiramer acetate is an approved medicine to treat patients with relapsing forms of MS. (Image Credits: Reuters) The U.S. Food and Drug Administration (FDA ...

It’s not known whether Copaxone (glatiramer acetate) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you should use the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals and patients with multiple sclerosis that treatment with ...

The drug, glatiramer acetate, is approved to treat patients with relapsing forms of multiple sclerosis, a chronic disease that affects the central nervous system. Teva markets the drug under the ...